Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
Biogen’s amyotrophic lateral sclerosis (ALS) treatment tofersen and Eli Lilly’s obesity drug tirzepatide are entering the final stretch of regulatory reviews in Japan, with a key health ministry advisory panel now scheduled to discuss their approval on December 2. The…
To read the full story
Related Article
- Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
- Biogen Files Tofersen as Japan’s 1st Genetic ALS Drug
May 22, 2024
- Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
- Argenx Seeks Label Expansion for Vyvdura in Japan
April 26, 2024
- Santen Seeks Japan Nod for Eye Drop Targeting Myopia
February 29, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
- PeptiDream to Codevelop Lilly's Alzheimer’s Diagnostic Tauvid in Japan
November 25, 2022
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…